Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...
In a groundbreaking initiative, the National Diabetes Association Ghana has announced the distribution of 300 boxes of ...
German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...
The Motley Fool on MSN11d
Is Merck Stock a Buy?Understanding the investment thesis for Merck requires appreciating the importance of its blockbuster cancer drug, Keytruda, ...
Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...
MilliporeSigma continued its march of manufacturing investments this year, revealing plans to pump $76 million into expanding ...
Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ...
Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ongoing sluggishness ...
Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback